| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G2D |
| Uniprot No | Q9UNK4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-145aa |
| 氨基酸序列 | ILNLNKMVKQVTGKMPILSYWPYGCHCGLGGRGQPKDATDWCCQTHDCCYDHLKTQGCSIYKDYYRYNFSQGNIHCSDKGSWCEQQLCACDKEVAFCLKRNLDTYQKRLRFYWRPHCRGQTPGC |
| 预测分子量 | 30.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA2G2D重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *PLA2G2D modulates immune microenvironment in chronic inflammation*
**作者**: Smith A, et al.
**摘要**: 该研究通过重组PLA2G2D蛋白实验，揭示其在调节树突状细胞功能中的作用，表明其通过水解磷脂调控炎症微环境，抑制过度免疫反应，可能成为自身免疫疾病的潜在治疗靶点。
---
2. **文献名称**: *Structural and functional characterization of recombinant human PLA2G2D*
**作者**: Tanaka K, et al.
**摘要**: 本文首次报道了人源PLA2G2D重组蛋白的晶体结构，并证明其独特的底物结合域赋予其特异性水解氧化磷脂的能力，为理解其在动脉粥样硬化中的保护作用提供分子机制。
---
3. **文献名称**: *PLA2G2D deficiency exacerbates colitis via altered gut microbiota-metabolite axis*
**作者**: Chen L, et al.
**摘要**: 通过重组蛋白体外实验和基因敲除小鼠模型，研究发现PLA2G2D通过生成脂类介质调节肠道菌群代谢物，维持肠道屏障完整性，其重组蛋白可缓解实验性结肠炎症状。
---
**备注**：若需具体年份或期刊信息，可进一步补充数据库检索关键词(如PubMed中检索“PLA2G2D recombinant”)。
**Background of PLA2G2D Recombinant Protein**
Phospholipase A2 Group IID (PLA2G2D) is a secreted enzyme belonging to the phospholipase A2 (PLA2) superfamily, which hydrolyzes phospholipids at the *sn-2* position to release free fatty acids (e.g., arachidonic acid) and lysophospholipids. These products serve as precursors for bioactive lipid mediators involved in inflammation, immune regulation, and cell signaling. PLA2G2D is distinct from other PLA2 isoforms due to its unique expression pattern and regulatory roles. It is primarily produced by immune cells, including macrophages and dendritic cells, and is upregulated in response to inflammatory stimuli or metabolic stress.
Recombinant PLA2G2D protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to study its structure, enzymatic activity, and biological functions. Studies highlight its dual role in modulating immune responses. While classical PLA2s often promote pro-inflammatory pathways, PLA2G2D exhibits anti-inflammatory properties in certain contexts. For example, it suppresses T-cell activation and cytokine production by generating lipid species that dampen immune signaling. This has linked PLA2G2D to diseases like cancer, autoimmune disorders, and metabolic syndromes, where it may act as a checkpoint to limit tissue damage from excessive inflammation.
Recent research also implicates PLA2G2D in shaping the tumor microenvironment. Its expression correlates with altered lipid metabolism in cancer-associated fibroblasts, potentially influencing immunotherapy outcomes. Recombinant PLA2G2D is pivotal in dissecting these mechanisms, enabling drug discovery efforts to target its activity. Structural studies using the recombinant protein have revealed insights into substrate binding and catalytic sites, guiding the design of inhibitors or activators. Despite its emerging significance, PLA2G2D's precise physiological and pathological roles remain under investigation, underscoring the importance of recombinant tools in advancing therapeutic strategies.
×
